查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1606698

糖尿病肾臟病变治疗市场：按治疗类型、最终用户划分 - 全球预测 2025-2030

Diabetic Nephropathy Treatment Market by Treatment Type (End-stage Renal Disease (ESRD) Treatment, Medications, Pharmacological Treatment), End-User (Hospitals, Nephrology Clinics) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年糖尿病肾臟病变治疗市场价值为22.6亿美元，预计到2024年将达到23.8亿美元，复合年增长率为5.46%，到2030年将达到32.8亿美元。

糖尿病肾臟病变的治疗，血管收缩素转化酵素（ACE）抑制剂、血管收缩素II受体阻断剂（ARB）、钠-葡萄糖共同输送体-2（SGLT2）抑制剂等药物用于併发症。这些治疗的需求源于全球糖尿病盛行率的不断上升，推动了对有效干预措施的巨大需求，以防止进展为末期肾病。主要用途包括减少蛋白尿、抑制肾功能下降和控制併发症。最终使用者主要是医院、肾臟病诊所和研究机构。该市场主要受到糖尿病人口增长、药物开发进步以及对早期诊断日益关注的影响。在对疾病病理生理学和遗传倾向的新见解的推动下，新型生技药品和精准医学代表着巨大的商机。然而，它也存在治疗成本高、潜在副作用和监管程序复杂等限制。此外，低收入地区的医疗保健系统多种多样，可近性问题也是市场成长的问题。创新可能会在开发对患者友好的配方（例如每週一次的口服药物）以及用于即时病患监测的数位健康解决方案的整合方面蓬勃发展。此外，针对多种途径的联合治疗的研究可能会提高治疗效果。市场的本质是高度动态和竞争的，主要製药公司都优先考虑研发以保持竞争优势。从策略上讲，研究和临床测试合作和联盟可以在克服现有挑战和进入开拓市场方面发挥至关重要的作用。透过专注于以患者为中心的进步并利用技术整合，公司可以在糖尿病肾臟病变治疗领域占据有利地位。

主要市场统计
基准年[2023] 22.6亿美元
预测年份 [2024] 23.8亿美元
预测年份 [2030] 32.8亿美元
复合年增长率（%） 5.46%

市场动态：揭示快速发展的糖尿病肾臟病变治疗市场的关键市场洞察

供需的动态交互作用正在改变糖尿病肾臟病变治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 由于老年人口的增加，全球糖尿病盛行率不断上升
    • 政府主导努力解决糖尿病及其併发症的负担
    • 越来越重视以病人为中心的糖尿病肾臟病护理计划
  • 市场限制因素
    • 糖尿病肾臟病变治疗费用高
  • 市场机会
    • 采用新的、更有效的糖尿病肾臟病变治疗方法
    • 完善糖尿病肾臟病变治疗报销政策与医疗应用
  • 市场问题
    • 糖尿病肾臟病变相关的合併症和治疗复杂性

波特五力：驾驭糖尿病肾臟病变治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势、解决弱点并避免潜在的挑战，以确保更强大的市场地位。

PESTLE分析：了解糖尿病肾臟病变治疗市场的外部影响

外部宏观环境因素在塑造糖尿病肾臟病变治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析：了解糖尿病肾臟病变治疗市场的竞争格局

对糖尿病肾臟病变治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示自己的竞争定位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：糖尿病肾臟病变治疗市场供应商的绩效评估

FPNV定位矩阵是评估糖尿病肾臟病变治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：制定糖尿病肾臟病变治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对糖尿病肾臟病治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3. 塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着人口老化的加剧，全球糖尿病盛行率正在上升
      • 政府主导努力解决糖尿病及其併发症的负担
      • 以患者为中心的糖尿病肾臟病护理计划变得越来越重要
    • 抑制因素
      • 糖尿病肾臟病变治疗费用上涨
    • 机会
      • 采用新的、更有效的糖尿病肾臟病治疗方法
      • 完善糖尿病肾臟病变治疗报销保单和医疗保险
    • 任务
      • 糖尿病肾臟病变相关的併发症和护理复杂性
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章糖尿病肾臟病变治疗市场：依治疗类型

  • 介绍
  • 末期肾功能衰竭（ESRD）的治疗
    • 肾臟透析
    • 移植
  • 药品
    • 血管收缩素2 受体阻断剂 (ARB)
    • 血管收缩素转化酵素(ACE) 抑制剂
    • 降低胆固醇药物
    • Metformin
  • 药物治疗

第七章 糖尿病肾臟病变治疗市场：依最终使用者分类

  • 介绍
  • 医院
  • 肾臟内科门诊

第八章北美及南美糖尿病肾臟病变治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太糖尿病肾臟病变治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲糖尿病肾臟病变治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • ChemoCentryx, Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International PLC
  • IQVIA Inc.
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Mesoblast Ltd
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-2A0283E25691

The Diabetic Nephropathy Treatment Market was valued at USD 2.26 billion in 2023, expected to reach USD 2.38 billion in 2024, and is projected to grow at a CAGR of 5.46%, to USD 3.28 billion by 2030.

Diabetic nephropathy treatment encompasses a range of therapeutics aimed at managing the complications of kidney damage due to diabetes, including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and sodium-glucose co-transporter-2 (SGLT2) inhibitors. The necessity for these treatments arises from the increasing prevalence of diabetes globally, prompting a significant demand for effective interventions to prevent the progression to end-stage renal disease. Key applications include reducing proteinuria, slowing renal function decline, and managing associated comorbidities. End-users predominantly comprise hospitals, nephrology clinics, and research institutes. The market is chiefly influenced by the growing diabetic population, advancements in drug development, and an increasing focus on early diagnostics. Novel biologics and precision medicine represent significant opportunities, driven by emerging insights into disease pathophysiology and genetic predispositions. However, limitations include the high cost of treatment, potential side effects, and complex regulatory procedures. Market growth is also challenged by varying healthcare systems and accessibility issues in lower-income regions. Innovation can thrive in developing patient-friendly formulations, like once-weekly oral drugs, and integrating digital health solutions for real-time patient monitoring. Additionally, research into combination therapies targeting multiple pathways could potentially enhance therapeutic efficacy. The nature of the market is highly dynamic and competitive, with major pharmaceutical companies prioritizing R&D to maintain competitive advantage. Strategically, collaborations and partnerships for research and clinical trials could be pivotal in overcoming existing challenges and accessing untapped markets. By focusing on patient-centric advancements and harnessing technological integrations, businesses can position themselves advantageously in the diabetic nephropathy treatment landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 2.26 billion
Estimated Year [2024] USD 2.38 billion
Forecast Year [2030] USD 3.28 billion
CAGR (%) 5.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Nephropathy Treatment Market

The Diabetic Nephropathy Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising global prevalence of diabetes with increasing geriatric population
    • Government-led initiatives to address the burden of diabetes and its complications
    • Growing emphasis on patient-centric care plans for diabetic nephropathy
  • Market Restraints
    • High cost of diabetic nephropathy treatments
  • Market Opportunities
    • Introduction of new and more effective diabetic nephropathy treatments
    • Improved reimbursement policies and healthcare coverage for diabetic nephropathy treatments
  • Market Challenges
    • Comorbidities and complexity of care associated with diabetic nephropathy

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Nephropathy Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Nephropathy Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Nephropathy Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Nephropathy Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Nephropathy Treatment Market

A detailed market share analysis in the Diabetic Nephropathy Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Nephropathy Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Nephropathy Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic Nephropathy Treatment Market

A strategic analysis of the Diabetic Nephropathy Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Nephropathy Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, ChemoCentryx, Inc., Daiichi Sankyo Company, Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Endo International PLC, IQVIA Inc., Johnson & Johnson Services, Inc., Mallinckrodt Pharmaceuticals, Merck & Co., Inc., Mesoblast Ltd, Novartis AG, Otsuka Pharmaceutical Co., Ltd., Pfizer, Inc., Reata Pharmaceuticals, Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Diabetic Nephropathy Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Type, market is studied across End-stage Renal Disease (ESRD) Treatment, Medications, and Pharmacological Treatment. The End-stage Renal Disease (ESRD) Treatment is further studied across Kidney Dialysis and Transplant. The Medications is further studied across Angiotensin 2 Receptor Blockers (ARBs), Angiotensin-converting Enzyme (ACE) Inhibitors, Cholesterol-lowering Drugs, and Metformin.
  • Based on End-User, market is studied across Hospitals and Nephrology Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising global prevalence of diabetes with increasing geriatric population
      • 5.1.1.2. Government-led initiatives to address the burden of diabetes and its complications
      • 5.1.1.3. Growing emphasis on patient-centric care plans for diabetic nephropathy
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of diabetic nephropathy treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of new and more effective diabetic nephropathy treatments
      • 5.1.3.2. Improved reimbursement policies and healthcare coverage for diabetic nephropathy treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Comorbidities and complexity of care associated with diabetic nephropathy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic Nephropathy Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. End-stage Renal Disease (ESRD) Treatment
    • 6.2.1. Kidney Dialysis
    • 6.2.2. Transplant
  • 6.3. Medications
    • 6.3.1. Angiotensin 2 Receptor Blockers (ARBs)
    • 6.3.2. Angiotensin-converting Enzyme (ACE) Inhibitors
    • 6.3.3. Cholesterol-lowering Drugs
    • 6.3.4. Metformin
  • 6.4. Pharmacological Treatment

7. Diabetic Nephropathy Treatment Market, by End-User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Nephrology Clinics

8. Americas Diabetic Nephropathy Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Nephropathy Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Nephropathy Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Aurobindo Pharma Limited
  • 6. Bayer AG
  • 7. Boehringer Ingelheim International GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. ChemoCentryx, Inc.
  • 10. Daiichi Sankyo Company, Limited
  • 11. Dr. Reddy's Laboratories Ltd.
  • 12. Eli Lilly and Company
  • 13. Endo International PLC
  • 14. IQVIA Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Mallinckrodt Pharmaceuticals
  • 17. Merck & Co., Inc.
  • 18. Mesoblast Ltd
  • 19. Novartis AG
  • 20. Otsuka Pharmaceutical Co., Ltd.
  • 21. Pfizer, Inc.
  • 22. Reata Pharmaceuticals, Inc.
  • 23. Sanofi SA
  • 24. Sun Pharmaceutical Industries Ltd.
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. DIABETIC NEPHROPATHY TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. DIABETIC NEPHROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. DIABETIC NEPHROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIABETIC NEPHROPATHY TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIABETIC NEPHROPATHY TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY KIDNEY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY ANGIOTENSIN 2 RECEPTOR BLOCKERS (ARBS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY CHOLESTEROL-LOWERING DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY PHARMACOLOGICAL TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY NEPHROLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-STAGE RENAL DISEASE (ESRD) TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DIABETIC NEPHROPATHY TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. DIABETIC NEPHROPATHY TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. DIABETIC NEPHROPATHY TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023